1. Simultaneous ABO-incompatible living-donor liver transplantation and splenectomy without plasma exchange in China: Two case reports
- Author
-
Xie Zhantao, Yuan Zhenhua, Xu Hua'en, Janbin Chen, Chen Yongfeng, Wang Weiwei, Janjun Sun, Guoyong Chen, Wang Bing, Liu Guangbo, Tang Gaofeng, Wei Sidong, Zhao Huibo, and Niu Biao
- Subjects
Adult ,Male ,China ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Basiliximab ,medicine.medical_treatment ,Splenectomy ,Case Report ,030230 surgery ,Liver transplantation ,Biochemistry ,splenectomy ,ABO Blood-Group System ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,ABO blood group system ,parasitic diseases ,Living Donors ,ABO-incompatible transplantation ,medicine ,Humans ,living-donor transplantation ,Critical condition ,Plasma Exchange ,liver transplantation ,treatment ,business.industry ,Biochemistry (medical) ,Anticoagulants ,Immunosuppression ,Cell Biology ,General Medicine ,biological factors ,Surgery ,Female ,030211 gastroenterology & hepatology ,Living donor liver transplantation ,business ,Follow-Up Studies ,medicine.drug - Abstract
ABO-incompatible (ABO-i) living-donor liver transplantation (LDLT) is performed if an ABO-compatible graft cannot be obtained. However, a perfect desensitization protocol has not been established worldwide, especially for simultaneous ABO-i LDLT and splenectomy. We herein report two cases of ABO-i LDLT. To the best of our knowledge, this is the first case report of ABO-i LDLT in an adult patient in China. Splenectomy and T-cell-targeted immunosuppression (basiliximab) was used to overcome the blood group barrier in these recipients. The patients had good graft function without signs of antibody-mediated rejection throughout the 12-month follow-up. Thus, ABO-i LDLT with splenectomy is undoubtedly life-saving when an ABO-compatible graft cannot be obtained for patients in critical condition.
- Published
- 2017
- Full Text
- View/download PDF